Briacell Therapeutics Corp

Company Profile

Briacell Therapeutics Corp had its IPO on 2021-02-24 under the ticker symbol BCTX.

The company operates in the Healthcare sector and Biotechnology industry. Briacell Therapeutics Corp has a staff strength of 0 employees.

Stock update

Shares of Briacell Therapeutics Corp opened at $6.24 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $6.04 - $6.5, and closed at $6.26.

This is a -1.42% slip from the previous day's closing price.

A total volume of 130,598 shares were traded at the close of the day’s session.

In the last one week, shares of Briacell Therapeutics Corp have slipped by -9.28%.

Briacell Therapeutics Corp's Key Ratios

Briacell Therapeutics Corp has a market cap of $101.32 million, indicating a price to book ratio of 8.7288 and a price to sales ratio of 0.

In the last 12-months Briacell Therapeutics Corp’s revenue was $0 with a gross profit of $0 and an EBITDA of $-19231526. The EBITDA ratio measures Briacell Therapeutics Corp's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Briacell Therapeutics Corp’s operating margin was 0% while its return on assets stood at -29.09% with a return of equity of -309.73%.

In Q0.33333333333333, Briacell Therapeutics Corp’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Briacell Therapeutics Corp’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-0.57 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Briacell Therapeutics Corp’s profitability.

Briacell Therapeutics Corp stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -1.2808. Its price to sales ratio in the trailing 12-months stood at 0.

Briacell Therapeutics Corp stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$34.16 million

Total Liabilities

$670413.00

Operating Cash Flow

$0

Capital Expenditure

$0

Dividend Payout Ratio

0%

Briacell Therapeutics Corp ended 2025 with $34.16 million in total assets and $0 in total liabilities. Its intangible assets were valued at $34.16 million while shareholder equity stood at $-1280586.00.

Briacell Therapeutics Corp ended 2025 with $0 in deferred long-term liabilities, $670413.00 in other current liabilities, 65589293.00 in common stock, $-73338140.00 in retained earnings and $0 in goodwill. Its cash balance stood at $33.50 million and cash and short-term investments were $33.50 million. The company’s total short-term debt was $0 while long-term debt stood at $0.

Briacell Therapeutics Corp’s total current assets stands at $33.94 million while long-term investments were $2.00 and short-term investments were $0. Its net receivables were $8928.00 compared to accounts payable of $582451.00 and inventory worth $0.

In 2025, Briacell Therapeutics Corp's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Briacell Therapeutics Corp paid $0 in dividends in 2025.

Other key metrics

Current Trading Price

$6.26

52-Week High

$8.37

52-Week Low

$4.23

Analyst Target Price

$25

Briacell Therapeutics Corp stock is currently trading at $6.26 per share. It touched a 52-week high of $8.37 and a 52-week low of $8.37. Analysts tracking the stock have a 12-month average target price of $25.

Its 50-day moving average was $6.69 and 200-day moving average was $6.56 The short ratio stood at 8.98 indicating a short percent outstanding of 0%.

Around 2369.7% of the company’s stock are held by insiders while 1514.8% are held by institutions.